trial

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

NCTId NCT02969382
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 245 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2018-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
245 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-12-05
Primary completion
2018-07-31
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

32 total
Little Rock, United StatesGarden Grove, United StatesPico Rivera, United StatesAtlanta, United StatesLake Charles, United StatesRichardson, United StatesGyöngyös, HungaryGyula, HungaryBucharest, RomaniaCraiova, RomaniaIași, RomaniaMatrosy, Russia

Linked catalysts

1
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic A — primary completion2018-07-31

Facts & assertions

4 sourced
Enrollment
245
Phase
PHASE2
Primary Completion Date
2018-07-31
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication